Key Highlights

  • 7.8% was the gain for Revvity (NYSE:RVTY) on November 3, 2026, after it raised its full-year forecast with third-quarter results released that day.
  • USD 728.9 million of third-quarter Revenue against USD 698.9 million, with pro forma organic growth of 7% and adjusted Earnings of USD 1.38 a share against USD 1.18.
  • USD 379.6 million of Life Sciences revenue, with pro forma organic growth of 9%, and USD 349.3 million of Diagnostics revenue, with pro forma organic growth of 5%.
  • USD 5.40 to USD 5.45 is the new pro forma adjusted earnings guidance for 2026 on about USD 2.86 billion of revenue, with organic growth of about 5%.

What Revvity Reported

Revvity reported third-quarter 2026 results on November 3, 2026, for the quarter ended October 4. Reported revenue was USD 728.9 million, up from USD 698.9 million, and pro forma organic growth was 7%. Adjusted earnings from continuing operations were USD 1.38 a share against USD 1.18, and GAAP earnings were USD 0.56 against USD 0.41. Life Sciences revenue was USD 379.6 million, with an adjusted Operating Margin of 31.5%. Diagnostics revenue was USD 349.3 million, down from USD 356.1 million as reported, with an adjusted operating margin of 29.9%. Shares closed up 7.84%, according to published market data. The reported figures differ from pro forma ones because the pro forma basis adjusts revenue to USD 709.6 million and pro forma adjusted earnings to USD 1.37, which is the basis management uses for guidance and for comparison with the prior year.

What the Raised Outlook Says

Pro forma figures adjust for portfolio changes, and Revvity's guidance excludes its China IDX business. The company now expects 2026 pro forma revenue of about USD 2.86 billion, organic growth of about 5% and pro forma adjusted earnings of USD 5.40 to USD 5.45 a share. The release says guidance was raised, but it does not state the prior range, so the size of the increase cannot be quantified here. The mix is worth noting: Life Sciences grew faster than Diagnostics, which reported a decline in reported revenue but 5% organic growth, so currency and portfolio effects explain part of the difference. Revvity (NYSE:RVTY) therefore leaves investors to compare pro forma growth, which management emphasizes, with reported revenue, which grew about 4.3% (simple arithmetic on USD 728.9 million against USD 698.9 million).

Risks and What to Watch Next

Revvity sells instruments and reagents to research labs, drug makers and diagnostic labs, so funding for academic research and Drug Development drives demand. Diagnostics growth of 5% organic is solid but slower than Life Sciences. Pro forma numbers can also hide restructuring effects, and the missing prior guidance range limits comparison. A 7.8% single-day rise raises expectations for the fourth quarter. Investors will watch Life Sciences organic growth, Diagnostics volumes, margins and any further portfolio changes, plus the next outlook update from the company. Diagnostics adjusted operating margin of 29.9% is a useful gauge of whether mix is stable, as is the Life Sciences margin of 31.5%.

Where Things Stand

Revvity can extend a 7.8% jump only if fourth-quarter organic growth stays near the roughly 5% it now guides for the year and margins hold. The latest quarter showed 7% organic growth, higher adjusted earnings and a raised forecast, which explains the gain. The limits are slower Diagnostics growth and the missing prior guidance range. For Revvity (NYSE:RVTY), the next catalyst is the fourth-quarter report. A one-day rally is not a forecast. Nothing here is Investment advice.